Literature DB >> 24151043

SEOM clinical guidelines for the management of metastatic breast cancer 2013.

A Llombart Cussac1, J de la Haba Rodríguez, A Ruiz Simón, I Álvarez López, J Cortés Castán.   

Abstract

Patients with metastatic breast cancer should be offered comprehensive and personalized medical attention including, but not limited to, psychosocial, supportive and symptom-related interventions. A large number of treatment options are available and several prognostic and predictive factors are useful to identify the best therapeutic options individually.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24151043     DOI： 10.1007/s12094-013-1095-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  19 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

3.  SEOM guidelines for the treatment of bone metastases from solid tumours.

Authors:  Javier Cassinello Espinosa; Aránzazu González Del Alba Baamonde; Fernando Rivera Herrero; Esther Holgado Martín
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

4.  SEOM clinical guidelines for the treatment of metastatic breast cancer.

Authors:  Isabel Alvarez López; Juan de la Haba Rodríguez; Amparo Ruiz Simón; Meritxell Bellet Ezquerra; Lourdes Calvo Martínez; Laura García Estévez; Álvaro Rodríguez Lescure; Dolores Isla Casado
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

Review 5.  Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  F Cardoso; M Castiglione
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

Review 6.  Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.

Authors:  Linda J M Oostendorp; Peep F M Stalmeier; A Rogier T Donders; Winette T A van der Graaf; Petronella B Ottevanger
Journal:  Lancet Oncol       Date:  2011-05-27       Impact factor: 41.316

7.  Progress against solid tumors in danger: the metastatic breast cancer example.

Authors:  Javier Cortés; Emiliano Calvo; Antonio González-Martín; Shaheenah Dawood; Antonio Llombart-Cussac; Leticia De Mattos-Arruda; Patricia Gómez; Orlando Silva; Edith A Perez; Hope S Rugo; Ana Lluch; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2012-08-27       Impact factor: 44.544

8.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

9.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Authors:  Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves
Journal:  Lancet       Date:  2011-03-02       Impact factor: 79.321

10.  Combination anastrozole and fulvestrant in metastatic breast cancer.

Authors:  Rita S Mehta; William E Barlow; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Danika L Lew; Daniel F Hayes; Julie R Gralow; Robert B Livingston; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2012-08-02       Impact factor: 91.245
View more
  3 in total

1.  SEOM guidelines 2013: a response to the needs of Spanish oncologists.

Authors:  J J Cruz-Hernández; C A Rodríguez
Journal:  Clin Transl Oncol       Date:  2013-08-08       Impact factor: 3.405

2.  Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel.

Authors:  Noelia Martínez-Jañez; Ignacio Chacón; Ana de Juan; Luis Cruz-Merino; Sònia Del Barco; Isaura Fernández; Paula García-Teijido; Amalia Gómez-Bernal; Arrate Plazaola; José Ponce; Sonia Servitja; Pilar Zamora
Journal:  Breast Care (Basel)       Date:  2016-02-08       Impact factor: 2.860

3.  Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.

Authors:  J Gavila; M Á Seguí; L Calvo; T López; J J Alonso; M Farto; R Sánchez-de la Rosa
Journal:  Clin Transl Oncol       Date:  2016-04-21       Impact factor: 3.405
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.